Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomes
Aim. To study the effectiveness and safety of clopidogrel and acetylsalicylic acid (ASA) in coronary atherosclerosis (CA) patients after coronary artery bypass graft surgery (CABG). To investigate intracellular metabolic activity of platelets and its association with platelet aggregation.Material an...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2009-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1360 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250420540571648 |
|---|---|
| author | Yu. I. Grinstein A. A. Savchenko I. V. Filonenko E. A. Savchenko |
| author_facet | Yu. I. Grinstein A. A. Savchenko I. V. Filonenko E. A. Savchenko |
| author_sort | Yu. I. Grinstein |
| collection | DOAJ |
| description | Aim. To study the effectiveness and safety of clopidogrel and acetylsalicylic acid (ASA) in coronary atherosclerosis (CA) patients after coronary artery bypass graft surgery (CABG). To investigate intracellular metabolic activity of platelets and its association with platelet aggregation.Material and methods. In total, 94 45-72-year-old men with coronary heart disease (CHD) and initially increased platelet aggregation (PLA) were randomised into two groups, receiving clopidogrel (75 mg/d; n=44) or ASA (75–100 mg/d; n=50). The patients not responding to the two-week therapy were regarded as therapy-resistant.Results. In CHD patients after CABG, ASA resistance developed in 24%. In contrast to ASA, clopidogrel action mechanisms are based on the inhibition of platelet energy metabolism, and increased substrate flow towards nonprotein synthesis in red blood cells. These features could explain the development of laboratory-diagnosed resistance for ASA, but not clopidogrel. End-point analysis demonstrated that clopidogrel is more effective than ASA in the prevention of acute coronary syndrome, de novo angina, and cardiovascular death during the two-year follow-up of the post-CABG patients.Conclusion. Clopidogrel therapy was not associated with laboratory-diagnosed resistance, and was more effective in terms of acute coronary event prevention than ASA. |
| format | Article |
| id | doaj-art-e7851de6cb30464babdfd101e3aa02f7 |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2009-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-e7851de6cb30464babdfd101e3aa02f72025-08-20T03:57:17Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252009-08-018836431070Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomesYu. I. Grinstein0A. A. Savchenko1I. V. Filonenko2E. A. Savchenko3V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University’Research Institute for Medical Problems of the North, Siberian Branch, Russian Academy of Medical SciencesV.F. Voyno-Yasenetsky Krasnoyarsk State Medical University’Regional Clinical HospitalAim. To study the effectiveness and safety of clopidogrel and acetylsalicylic acid (ASA) in coronary atherosclerosis (CA) patients after coronary artery bypass graft surgery (CABG). To investigate intracellular metabolic activity of platelets and its association with platelet aggregation.Material and methods. In total, 94 45-72-year-old men with coronary heart disease (CHD) and initially increased platelet aggregation (PLA) were randomised into two groups, receiving clopidogrel (75 mg/d; n=44) or ASA (75–100 mg/d; n=50). The patients not responding to the two-week therapy were regarded as therapy-resistant.Results. In CHD patients after CABG, ASA resistance developed in 24%. In contrast to ASA, clopidogrel action mechanisms are based on the inhibition of platelet energy metabolism, and increased substrate flow towards nonprotein synthesis in red blood cells. These features could explain the development of laboratory-diagnosed resistance for ASA, but not clopidogrel. End-point analysis demonstrated that clopidogrel is more effective than ASA in the prevention of acute coronary syndrome, de novo angina, and cardiovascular death during the two-year follow-up of the post-CABG patients.Conclusion. Clopidogrel therapy was not associated with laboratory-diagnosed resistance, and was more effective in terms of acute coronary event prevention than ASA.https://cardiovascular.elpub.ru/jour/article/view/1360coronary heart diseasecoronary artery bypass graft surgeryclopidogrelacetylsalicylic acidacute coronary event prevention |
| spellingShingle | Yu. I. Grinstein A. A. Savchenko I. V. Filonenko E. A. Savchenko Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomes Кардиоваскулярная терапия и профилактика coronary heart disease coronary artery bypass graft surgery clopidogrel acetylsalicylic acid acute coronary event prevention |
| title | Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomes |
| title_full | Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomes |
| title_fullStr | Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomes |
| title_full_unstemmed | Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomes |
| title_short | Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomes |
| title_sort | zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention main results of the zeus study medication effectiveness acetylsalicylic acid resistance mechanisms short and long term clinical outcomes |
| topic | coronary heart disease coronary artery bypass graft surgery clopidogrel acetylsalicylic acid acute coronary event prevention |
| url | https://cardiovascular.elpub.ru/jour/article/view/1360 |
| work_keys_str_mv | AT yuigrinstein zylltandacetylsalicylicacidincoronaryatherosclerosispatientsaftercoronaryarterybypassgraftinterventionmainresultsofthezeusstudymedicationeffectivenessacetylsalicylicacidresistancemechanismsshortandlongtermclinicaloutcomes AT aasavchenko zylltandacetylsalicylicacidincoronaryatherosclerosispatientsaftercoronaryarterybypassgraftinterventionmainresultsofthezeusstudymedicationeffectivenessacetylsalicylicacidresistancemechanismsshortandlongtermclinicaloutcomes AT ivfilonenko zylltandacetylsalicylicacidincoronaryatherosclerosispatientsaftercoronaryarterybypassgraftinterventionmainresultsofthezeusstudymedicationeffectivenessacetylsalicylicacidresistancemechanismsshortandlongtermclinicaloutcomes AT easavchenko zylltandacetylsalicylicacidincoronaryatherosclerosispatientsaftercoronaryarterybypassgraftinterventionmainresultsofthezeusstudymedicationeffectivenessacetylsalicylicacidresistancemechanismsshortandlongtermclinicaloutcomes |